COVID-19 vaccine: Bharat Biotech asked to submit complete ph 2 data before ph 3 trial
Bharat Biotech had sought DCGI’s nod for conducting phase-3 clinical trials of its COVID-19 vaccine, now it has been asked to submit complete safety and immunogenicity data of the ongoing phase-2 trial, besides providing some clarifications, before proceeding for the next stage.
The vaccine ‘Covaxin’ is being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
According to the officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase-3 randomized double-blind placebo-controlled multi-centre trial of its COVID-19 vaccine candidate.
The firm in its application said that the study would cover 28,500 subjects aged 18 years and above and would be conducted in 19 sites; including Delhi, Mumbai, Patna and Lucknow; across 10 states.
According to the sources, the phase-2 trial of the Covaxin is going on and the second dose is yet to be given to volunteers at some sites.
An official informed, “The Company presented phase-3 clinical trial protocol along with interim data of phase 1 and 2 clinical trials,”
The subject expert committee (SEC) at the Central Drugs Standard Control Organization (CDSCO) deliberated on the application on October 5.
“After a detailed deliberation, the committee opined that the design of the phase-3 study is in principle satisfactory except for clarification on definition of asymptomatic, etc. However, the study should be initiated with appropriate dose identified from the phase-2 safety and immunogenicity data. Accordingly, the firm should submit safety and immunogenicity data from phase-2 trial for consideration,” the panel said.
A source said, the SEC during its discussion also observed that the vaccine was well-tolerated in all dose groups and no serious adverse events have been reported so far.
The most common adverse event was pain at the injection site, which resolved transiently, the source added.
Also Read | This mental health awareness week, know the IMPORTANCE to have a good mental health
The phase-3 clinical trial application proposed a dose of 0.5 ml on day 0 and 28, sources mentioned.
Besides, Bharat Biotech, indigenously developed vaccine candidate by Zydus Cadila Ltd is in the phase 2 of the human clinical trials.
-PTC News
